Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial

What this study found

DIM did not show a clear short-term benefit for cervical lesion regression or HPV clearance. At 6 months, CIN2 or worse occurred in 8.8% of the DIM group versus 12.4% of placebo (RR 0.70; 95% CI: 0.4-1.2), and CIN3 or worse occurred in 4.6% versus 5.1% (RR 0.9; 95% CI: 0.4-2.0). Negative cytology, colposcopy, and HPV tests were seen in 27% versus 34% (RR 0.8; 95% CI: 0.6-1.0), and HPV-positive status among those HPV-positive at baseline was 69% (114/166) versus 61% (43/71) (RR 1.1; 95% CI: 0.9-1.4). Overall, 150 mg/day DIM was well tolerated but unlikely to affect cytology or HPV infection…

Study & population

Double-blind, randomised, controlled trial in adult women with newly diagnosed low-grade cervical cytological abnormalities identified through Cervical Screening Wales in South East Wales.

Intervention

Diindolylmethane (DIM; BioResponse DIM) was given as 150 mg/day by oral capsule for 6 months.

Key limitation

The follow-up period was only 6 months, which limits assessment of longer-term lesion progression or clearance.

View full study detailsView sourceOpen PDF